MedTrace Logo

Integrated Molecular Analysis of Cancer (IMAC)

NCT02078544 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1800

Last updated 2023-11-09

No results posted yet for this study

Summary

The purpose of the study is to identify biomarkers and potentially actionable mutations/ activated molecular pathways and evaluate the impact of molecular profiling information on patients with cancer.

The hypothesis of the study are:

* Analysis of tumour samples will allow us to identify novel and/or actionable molecular changes that may drive therapeutic strategies for the management of cancers.
* Molecular profiling will improve the outcome of novel targeted-agent treatment in clinical trials
* Molecular profiling of paired samples (primary/recurrent and primary/metastatic) will provide new insights into mechanisms underlying drug resistance and metastasis in cancers.

Conditions

Interventions

OTHER

Integrated Molecular Analysis

Sponsors & Collaborators

  • National University Hospital, Singapore

    lead OTHER

Eligibility

Min Age
21 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2024-12-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02078544 on ClinicalTrials.gov